Gatehouse Bio, Inc.

DUBLIN, Jan. 12, 2024 /PRNewswire/ -- The "AstraZeneca Plc - Digital Transformation Strategies" company profile has been added to ResearchAndMarkets.com's offering. This report provides insight into AstraZeneca's tech activities, including its digital transformation strategies, its innovation programs, its technology initiatives, its estimated ICT budget, and its major ICT contracts. AstraZeneca Plc (AstraZeneca) is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection, and neurological diseases. The company's product portfolio includes biologics, prescription pharmaceuticals, and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors, and local representative offices. The company markets its products to primary care and specialty care physicians. Scope AstraZeneca is implementing AI technology to gain better understanding of diseases, identify targets for novel medicines, and enable its scientists to discover and develop new medicines. AstraZeneca launched Machine Learning Ledger Orchestration for Drug Discovery (MELLODDY), a research consortium to leverage machine learning technologies and accelerate drug discovery. AstraZeneca is building internal IT infrastructure and data analytics capabilities to experiment with both structured and unstructured big data to improve data governance and achieve operational efficiencies. AstraZeneca setup an in-house IT division in India, as part of its strategy to transform and streamline its IT operations. AstraZeneca is focusing on building digital factory of the future by testing and creating integrated solutions in its in-house labs. The technology focus of its in-house labs includes image recognition, AI, electronic records, digital twins, robotics, and automation. AstraZeneca operates Healthcare IoT Innovation Center in China responsible for developing smart healthcare solutions to improve patient experience. Reasons to Buy Gain insights into AstraZeneca's tech operations. Gain insights into its tech strategies and innovation initiatives. Gain insights into its technology themes under focus. Gain insights into various product launches, partnerships, and acquisition strategies. Key Topics Covered: Overview Digital Transformation Strategy Accelerators, Incubators, and Other Innovation Programs Technology Focus Technology Initiatives Acquisitions Partnership and Acquisition Network Map ICT Budget and Contracts Key Executives A selection of companies mentioned in this report includes Phyathai 2 Hospital Genomenon AliveCor G42 Healthcare NVIDIA Mila Qure.ai Gatehouse Bio Schrodinger BenevolentAI DeepMatter BERG docdok.health IgniteData IBM DNAnexus For more information about this company profile visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Company’s proprietary Code-Breaker™ Platform is expanding and characterizing the landscape of functional small RNA (sRNA) isoforms and using AI to model their role in disease, identify patient subsets, and digitally design precision oligonucleotide therapeutics BOSTON--(BUSINESS WIRE)-- Gatehouse Bio, a TechBio company utilizing AI to decode the landscape of small RNAs (sRNAs) and digitally design precision oligonucleotide therapeutics, announced today that its Chief Executive Officer, David W. Salzman, PhD, will present at the upcoming RNA Leaders Europe Congress, in Basel, Switzerland on March 15, 2023 at 12:20PM CET. In the presentation, Dr. Salzman will describe Gatehouse Bio’s AI-powered Code-Breaker™ Platform and discuss one of the company’s preclinical drug candidates, GHB1589M, an inhaled oligonucleotide therapeutic for idiopathic pulmonary fibrosis, or IPF. sRNAs control mRNA protein translation. When combinations of genetic and environmental factors impact sRNAs, diseases can manifest and progress. While sRNAs are known to drive the biology of countless diseases, the ability to discover and predict the precise sRNA isoforms that cause disease and correct their mechanism has eluded basic research. Gatehouse Bio’s Code-Breaker™ Platform has decoded the sRNA landscape into millions of structure and activity relationship features to model their role in various diseases. This has enabled Gatehouse Bio to identify patient subsets, predict the biological effect and safety of therapeutic intervention, and digitally design targeted oligonucleotide therapeutics. Over the last two years, Gatehouse Bio has used Code-Breaker to analyze multiple diseases and identify hotspots where there is high isoform burden. These hotspots have created a portfolio of novel drug targets, each of which has relevance across several diseases, creating the opportunity for deep pipeline growth. Gatehouse Bio is currently developing its lead targets into biomarker-guided precision therapies for the treatment of pulmonary, cardiac, neurological, and autoimmune diseases. Code-Breaker’s capabilities can be applied to the discovery and design of oligonucleotide therapeutics for a significantly broader range of diseases than the company’s initial focus areas. About Gatehouse Bio Gatehouse Bio is a TechBio company decoding small RNA (sRNA) isoforms to develop biomarker-guided precision oligonucleotide therapeutics. Using its AI-powered Code-Breaker™ Platform, Gatehouse Bio is expanding and characterizing the functional landscape of sRNAs, discovering disease-associated isoforms, and digitally designing therapeutics to counteract their effect. For more information visit gatehousebio.com and follow us on LinkedIn and Twitter.

Collaboration will advance the development of compounds designed by Gatehouse Bio’s AI-Powered platform BOSTON--(BUSINESS WIRE)-- Gatehouse Bio, a pioneer in small RNA therapeutics, and AstraZeneca, a global, science-led biopharmaceutical company, are advancing their partnership, to create RNA therapeutics for the treatment of heart failure with preserved ejection fraction (HFpEF). HFpEF is a heterogenous condition complicated by multiple interrelated diseases. In a prior study, Gatehouse Bio discovered mutations in small RNA genes that correlate to microvascular dysfunction and were predicted to regulate biological pathways associated with the clinical syndrome. “Our ability to identify small RNA mutations opens a novel class of targetable biology and an opportunity for a portfolio of oligonucleotide therapeutics that target specific groups of patients,” said Neal Foster, CBO at Gatehouse Bio. This collaboration brings together AstraZeneca’s scientific expertise and investment in RNA therapeutics with Gatehouse Bio’s ability to design disease modifying small RNA compounds. The collaboration is expected to accelerate the development of a broad range of novel therapeutics leveraging the unexplored small non-coding area of the genome. Dr. David W. Salzman, CEO of Gatehouse Bio comments: "Over the last 3 years we’ve been characterizing small RNA mutations and developing knowledge graphs to model their role in disease. The collaboration with AstraZeneca moves us closer towards realizing our vision of bringing therapeutics from discovery to patients.” Dr. Shalini Andersson, Vice President of Oligonucleotide Discovery at AstraZeneca comments: “Gatehouse Bio’s expertise and platform in small RNA together with our own scientific expertise presents a significant opportunity for targeting the drivers of disease in heart failure. Together, we are steadily closing the gap between RNA modality, AI, and disease biology with the shared goal of discovering and developing novel treatments in heart failure.” About Gatehouse Bio Gatehouse Bio is a biotech company developing effective therapeutics using AI that harnesses the power of small RNA. Their platform discovers disease-associated mutations and designs therapeutics to counteract their effect. For more information visit and follow us on Twitter @gatehousebio